GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Operating Margin %

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Operating Margin % : 0.00% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Regencell Bioscience Holdings's Operating Income for the six months ended in Jun. 2023 was $-2.84 Mil. Regencell Bioscience Holdings's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Regencell Bioscience Holdings's Operating Margin % for the quarter that ended in Jun. 2023 was 0.00%.

The historical rank and industry rank for Regencell Bioscience Holdings's Operating Margin % or its related term are showing as below:


RGC's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.075
* Ranked among companies with meaningful Operating Margin % only.

Regencell Bioscience Holdings's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Regencell Bioscience Holdings's Operating Income for the six months ended in Jun. 2023 was $-2.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-6.27 Mil.

Warning Sign:

Regencell Bioscience Holdings Ltd has never been profitable in the past 3 years. It lost money every year.


Regencell Bioscience Holdings Operating Margin % Historical Data

The historical data trend for Regencell Bioscience Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Operating Margin % Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Operating Margin %
- - - - -

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Operating Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Regencell Bioscience Holdings's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Operating Margin % falls into.



Regencell Bioscience Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Regencell Bioscience Holdings's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-6.274 / 0
= %

Regencell Bioscience Holdings's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-2.844 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings  (NAS:RGC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Regencell Bioscience Holdings Operating Margin % Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus